Argent BioPharma and AusCann Forge Strategic Partnership to Advance Cannabinoid Drug Development

Argent Biopharma ( (AU:RGT) ) has provided an announcement.

Argent BioPharma and AusCann have entered into a Strategic Heads of Agreement to enhance cannabinoid drug development. This collaboration will leverage proprietary datasets and regulatory expertise from both companies to streamline regulatory submissions and improve market readiness. AusCann will license Argent’s CannEpil® CMC and Dossier for non-epilepsy pharmaceutical programs, ensuring no competition with Argent’s existing epilepsy-focused products. The agreement includes a deferred licensing fee structure with royalties on future products, aiming to accelerate drug development timelines and reduce regulatory costs. The partnership is expected to unlock new opportunities in cannabinoid-based pharmaceutical development, enhancing both companies’ industry positioning.

More about Argent Biopharma

Argent BioPharma Limited (ASX: RGT) is a clinical-stage biopharmaceutical company specializing in neuroimmunology and advanced nanomedicine. The company focuses on developing cannabinoid-based therapeutics and neuroimmune modulation, with a robust pipeline including products like CannEpil®, CogniCann®, and CimetrA® targeting CNS disorders and immune-related conditions.

YTD Price Performance: -20.83%

Average Trading Volume: 490

Technical Sentiment Signal: Buy

Current Market Cap: $6.71M

See more data about RGT stock on TipRanks’ Stock Analysis page.